- CLINICAL PROFESSOR Urology
- CLINICAL PROFESSOR Radiation Oncology
- CLINICAL PROFESSOR Oncological Sciences
Benisovich VI, Silverman L, Stone N, Cohen E. Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Cancer 1996; 77(1): 160-163.
Ferrari AC, Stone NN, Stock R, Esseesse I, Baldwin Y, Eyler JN, Gao M, Unger P, Mandeli J. New strategies of treatment and staging of prostate cancer. Cancer Invest 1998; 16(Suppl. 1).
Stock R, Ferrari AC, Stone NN. Is there a role for prophylactic pelvic radiation in the radiotherapeutic management of prostate cancer?. Oncology 1998; 12(10): 1467-1472.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Stone during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Bayer; Dendreon Corporation; Janssen Biotech, Inc., formerly Centocor Biotech, Inc.; Nucletron (Elekta)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.